EUVIMEDEUVIMED entdecken
Crossref

Exploring chromone‐2‐carboxamide derivatives for triple‐negative breast cancer targeting EGFR, FGFR3, and VEGF pathways: Design, synthesis, and preclinical insights

Dalia S El-Gamil, Mohamed Y Zaky, Patrick M Maximous iD, Marwa Sharaky, Ahmed M El-Dessouki, Noura M Riad, Saad Shaaban, Mohammad Abdel-Halim iD, Ahmed A Al-Karmalawy iD

Drug Development Research · 2024

DOI: 10.1002/ddr.22228 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2024. Verfasst von Dalia S El-Gamil und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt. Hauptthemen laut MEDLINE: ErbB Receptors, Triple Negative Breast Neoplasms, Vascular Endothelial Growth Factor A, Antineoplastic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chromone‐based compounds have established cytotoxic, antiproliferative, antimetastatic, and antiangiogenic effects on various cancer cell types via modulating different molecular targets. Herein, 17 novel chromone‐2‐carboxamide derivatives were synthesized and evaluated for their in vitro anticancer activity against 15 human cancer cell lines. Among the tested cell lines, MDA‐MB‐231, the triple‐negative breast cancer cell line, was found to be the most sensitive, where the N ‐(2‐furylmethylene) ( 15 ) and the α‐methylated N ‐benzyl ( 17 ) derivatives demonstrated the highest growth inhibition with GI 50 values of 14.8 and 17.1 μM, respectively. In vitro mechanistic studies confirmed the significant roles of compounds 15 and 17 in the induction of apoptosis and suppression of EGFR, FGFR3, and VEGF protein levels in MDA‐MB‐231 cancer cells. Moreover, compound 15 exerted cell cycle arrest at both the G0‐G1 and G2‐M phases. The in vivo efficacy of compound 15 as an antitumor agent was further investigated in female mice bearing Solid Ehrlich Carcinoma. Notably, administration of compound 15 resulted in a marked decrease in both tumor weight and volume, accompanied by improvements in biochemical, hematological, histological, and immunohistochemical parameters that verified the repression of both angiogenesis and inflammation as additional Anticancer mechanisms. Moreover, the binding interactions of compounds 15 and 17 within the binding sites of all three target receptors (EGFR, FGFR3, and VEGF) were clearly illustrated using molecular docking.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsTriple Negative Breast NeoplasmsVascular Endothelial Growth Factor AAntineoplastic AgentsReceptor, Fibroblast Growth Factor, Type 3Molecular Docking SimulationChromonesHumansFemaleAnimalsCell Line, TumorMiceDrug DesignApoptosisCell Proliferation

Stichwörter der Autor:innen

EGFRFGFR3VEGFanticancer agentschromonetriple‐negative breast cancer

Substanzen

ErbB ReceptorsVascular Endothelial Growth Factor AAntineoplastic AgentsReceptor, Fibroblast Growth Factor, Type 3EGFR protein, humanChromonesFGFR3 protein, humanVEGFA protein, human

Autor:innen und Institutionen

  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.
  • Zoology Department, Molecular Physiology Division, Faculty of Science, Beni-Suef University, Beni Suef, Egypt.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt.
  • Cancer Biology Department, Pharmacology Unit, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.
  • Biochemistry Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.
  • Pharmacology and Toxicology Department, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.

ORCID-Profile: Patrick M Maximous, Mohammad Abdel-Halim, Ahmed A Al-Karmalawy

Förderung

  • Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia

Zitieren

APA

El-Gamil, D. S., Zaky, M. Y., Maximous, P. M., Sharaky, M., El-Dessouki, A. M., Riad, N. M., Shaaban, S., Abdel-Halim, M., & Al-Karmalawy, A. A. (2024). Exploring chromone‐2‐carboxamide derivatives for triple‐negative breast cancer targeting EGFR, FGFR3, and VEGF pathways: Design, synthesis, and preclinical insights. Drug Development Research. https://doi.org/10.1002/ddr.22228

Vancouver

El-Gamil DS, Zaky MY, Maximous PM, Sharaky M, El-Dessouki AM, Riad NM, et al. Exploring chromone‐2‐carboxamide derivatives for triple‐negative breast cancer targeting EGFR, FGFR3, and VEGF pathways: Design, synthesis, and preclinical insights. Drug Development Research. 2024. doi:10.1002/ddr.22228

BibTeX
@article{ElGamil2024,
  author = {El-Gamil, Dalia S and Zaky, Mohamed Y and Maximous, Patrick M and Sharaky, Marwa and El-Dessouki, Ahmed M and Riad, Noura M and Shaaban, Saad and Abdel-Halim, Mohammad and Al-Karmalawy, Ahmed A},
  title = {Exploring chromone‐2‐carboxamide derivatives for triple‐negative breast cancer targeting EGFR, FGFR3, and VEGF pathways: Design, synthesis, and preclinical insights},
  journal = {Drug Development Research},
  year = {2024},
  doi = {10.1002/ddr.22228}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche